Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Bioserve Biotechnologies India is an Indian biotechnology and clinical diagnostics service provider, now part of Japan’s REPROCELL Group. The website positions the company as a leading oligonucleotide synthesis service provider in India, with a focus on early cancer diagnosis, molecular services, stem cell/iPSC-related products, and immuno-oncology research support. It is worth noting that, based on the captured website content, this is not a typical SaaS or enterprise software product, but rather a provider centered on laboratory testing, synthesis, and outsourced research services.
Its core modules include Oligosynthesis, Sanger sequencing, next-generation sequencing, microbial identification, DNA Barcoding, gene expression analysis, genotyping, and the PreciONC tumor testing panel. Its oligonucleotide synthesis services cover Long Mer, Modified DNA Oligos, NGS Grade Oligos, and Universal Primer, with mentions of high-throughput automated equipment, GMP procedures, batch records, and traceability. Its neoantigen detection service is relatively comprehensive, including WES, RNA-Seq, HLA/MHC binding prediction, TMB reporting, and a prioritized neoantigen list, with a stated TAT of 30 days after sample receipt.
The website’s resources page mentions downloadable 2024–2025 price lists and oligonucleotide order forms, but the main content does not disclose specific pricing, packages, payment methods, or service SLAs. The service model appears to be more project-based or quoted by sample and test type, rather than a subscription-based SaaS model.
Its strengths are that its service lines cover scientific research, clinical diagnostics, precision oncology, and stem cell research, backed by more than 20 years of experience, customer testimonials, and the global resources of REPROCELL. The sample requirements, report contents, and workflow for neoantigen detection are also described relatively clearly. Its weaknesses are the lack of details on software platform capabilities, such as an online dashboard, team collaboration, permissions, APIs, auditing, and data security compliance specifics. A certifications page exists, but the captured main content does not show the specific certification names.
It is better suited for university laboratories, hospitals/diagnostic labs, biotechnology companies, pharmaceutical R&D teams, and preclinical immuno-oncology teams for sequencing, primer synthesis, tumor panel testing, and neoantigen discovery. The captured content does not provide information on access from China, so this is considered unknown. If cross-border samples or clinical data are involved, logistics, compliance, and data export requirements should be confirmed separately.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on bioserve.in official site.
bioserve.in is an India Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach bioserve.in directly.